At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
FATE Fate Therapeutics
Trading 05-21 15:14:10 EDT
2.08
+0.24
+12.77%
High2.11Low1.79Vol3.62M
Open1.79D1 Closing1.84Amplitude17.66%
Mkt Cap241.25MTradable Cap209.15MTotal Shares116.26M
T/O7.34MT/O Rate3.60%Tradable Shares100.80M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
THOMSON REUTERS  ·  05-21 20:30
Fate Therapeutics Announces Presentations at 2026 Asco and Eular Annual Meetings Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
GlobeNewswire  ·  05-21 20:30
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics assumed with a Buy at Jefferies
TIPRANKS  ·  05-20 03:15
Fate Therapeutics assumed with a Buy at Jefferies
Wells Fargo Remains a Hold on Fate Therapeutics (FATE)
TIPRANKS  ·  05-14
Wells Fargo Remains a Hold on Fate Therapeutics (FATE)
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
TIPRANKS  ·  05-13
Fate Therapeutics reports Q1 EPS (26c), consensus (28c)
Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Reuters  ·  05-13
Fate Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028
Reuters  ·  05-13
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Benzinga  ·  05-13
Fate Therapeutics Q1 EPS $(0.26) Beats $(0.28) Estimate, Sales $1.299M Beat $1.139M Estimate
Fate Therapeutics Q1 FY26 net loss narrows 17.04% to $31.21 million
Reuters  ·  05-13
Fate Therapeutics Q1 FY26 net loss narrows 17.04% to $31.21 million
Fate Therapeutics Q1 Operating Expenses USD 34.299 Million
THOMSON REUTERS  ·  05-13
Fate Therapeutics Q1 Operating Expenses USD 34.299 Million
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
GlobeNewswire  ·  05-13
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics says FT819 achieves low disease activity in SLE without chemotherapy conditioning
Reuters  ·  05-11
Fate Therapeutics says FT819 achieves low disease activity in SLE without chemotherapy conditioning
Fate Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Reuters  ·  05-08
Fate Therapeutics Inc expected to post a loss of 28 cents a share - Earnings Preview
Piper Sandler Remains a Buy on Fate Therapeutics (FATE)
TIPRANKS  ·  05-06
Piper Sandler Remains a Buy on Fate Therapeutics (FATE)
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
GlobeNewswire  ·  05-05
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics posts Phase 1 FT819 lupus data showing B-cell remodeling without chemo conditioning
Reuters  ·  05-04
Fate Therapeutics posts Phase 1 FT819 lupus data showing B-cell remodeling without chemo conditioning
Fate Therapeutics Announces Three Presentations at the 2026 Asgct Annual Meeting Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
THOMSON REUTERS  ·  05-04
Fate Therapeutics Announces Three Presentations at the 2026 Asgct Annual Meeting Highlighting off-the-Shelf Car T-Cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
GlobeNewswire  ·  05-04
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones  ·  05-04
Fate Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright
TIPRANKS  ·  05-04
Fate Therapeutics price target raised to $7 from $5 at H.C. Wainwright

Introduction

Company Name.
Fate Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Issue price:
--